Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 3, 2013European Heart JournalOpen Access

The Year in Cardiology 2012: focus on cardiovascular disease prevention

View Full Paper
Ask AI
Bookmark
Share

Key result

A 2012 review highlighted advances in cardiovascular disease prevention, including new European guidelines, biomarkers, imaging techniques, and lifestyle and pharmacological interventions.

Design

Review

Authors

MCMarietta CharakidaPediatric CardiologySMStefano MasiPreventive Cardiology
John Deanfield
John DeanfieldUniversity College London

Discussion

Loading...

Member takes

Overview

2012 prevention review provides historical benchmark; leaves open how subsequent evidence has updated guidelines and interventions.

PICO

P
Population
Cardiovascular disease
I
Intervention / Comparator
Cardiovascular disease prevention strategies

A 2012 review summarizing European guidelines, biomarkers, imaging, and lifestyle/pharmacological advances in cardiovascular disease prevention.

Cite This Study

Charakida et al. (2013) conducted a review in Cardiovascular disease. Cardiovascular disease prevention strategies was evaluated. A 2012 review highlighted advances in cardiovascular disease prevention, including new European guidelines, biomarkers, imaging techniques, and lifestyle and pharmacological interventions.

synapsesocial.com/papers/6a92a26efa60aefc093ac40fhttps://doi.org/10.1093/eurheartj/ehs429
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lifetime Risks of Cardiovascular Disease2012 · 935 citations
  2. 2Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project2012 · 73 citations
  3. 3Heart Disease and Stroke Statistics—2012 Update2011 · 7,237 citations
  4. 4Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials2011 · 71 citations
  5. 5Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial2012 · 219 citations